About Integral membrane protein GPR180
Integral membrane protein GPR180 (GPR180) is a protein
from Homo sapiens identified by UniProt accession
Q86V85, 440 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Integral membrane protein GPR180 |
| UniProt accession | Q86V85 |
| Gene | GPR180 |
| Organism | Homo sapiens |
| Length | 440 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- alkaline phosphatase measurement · score 0.46
- triglyceride measurement · score 0.45
- HbA1c measurement · score 0.30
- sex hormone-binding globulin measurement · score 0.29
- apolipoprotein A 1 measurement · score 0.17
- serum alanine aminotransferase measurement · score 0.14
- PHF-tau measurement · score 0.10
- hair color · score 0.10
- hair colour measurement · score 0.08
- metabolite measurement · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86V85-F1 | alphafold | PREDICTED | 81.20 | — |
Amino-acid sequence (440 residues)
MGGLRLLAVA LTCCWWPQGS QGKTLRGSFS STAAQDAQGQ RIGHFEFHGD HALLCVRINN IAVAVGKEAK LYLFQAQEWL KLQQSSHGYS CSEKLSKAQL TMTMNQTEHN LTVSQIPSPQ TWHVFYADKY TCQDDKENSQ VEDIPFEMVL LNPDAEGNPF DHFSAGESGL HEFFFLLVLV YFVIACIYAQ SLWQAIKKGG PMHMILKVLT TALLLQAGSA LANYIHFSSY SKDGIGVPFM GSLAEFFDIA SQIQMLYLLL SLCMGWTIVR MKKSQSRPLQ WDSTPASTGI AVFIVMTQSV LLLWEQFEDI SHHSYHSHHN LAGILLIVLR ICLALSLGCG LYQIITVERS TLKREFYITF AKGCILWFLC HPVLACISVI FSDYQRDKVI TIGVILCQSV SMVILYRLFL SHSLYWEVSS LSSVTLPLTI SSGHKSRPHF
Explore Integral membrane protein GPR180 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets